• Market Capitalisation market-capitalisation-info $46 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-29 Mln

SAB Biotherapeutics Inc. (SABS) Share Price

$0.87

As on 06-Dec-2023 15:59 EST

up-down-arrow $-0.01-0.58%

  • Prev Close info

    $0.88

  • Day's Openinfo

    $0.88

  • Today's Highinfo

    $0.88

  • Today's Lowinfo

    $0.86

  • Today's Volumeinfo

    19,078

  • 52 Week rangeinfo

    $0.37 - 1.45

Please wait...

SAB Biotherapeutics Inc. (SABS) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
SAB Biotherapeutics (SABS)
47.47 -12.14 26.07 -18.70 -- -- --
S&P BSE Sensex*
14.36 7.11 5.61 11.10 15.57 14.53 12.73
#
-- -- -- -- -- -- --
As on 06-Dec-2023  |  *As on 07-Dec-2023  |  #As on
2022
SAB Biotherapeutics (SABS)
-92.45
S&P BSE Sensex
4.44
S&P BSE Sensex
4.44

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

SAB Biotherapeutics Inc. (SABS) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of SAB Biotherapeutics Inc. (SABS)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of SAB Biotherapeutics Inc. (SABS)

        Exec. Chairman

        Mr. Samuel J. Reich

        Co-Founder, Pres, CEO & Director

        Dr. Eddie Joe Sullivan Ph.D.

        Headquarters

        Sioux Falls, SD

        FAQs for SAB Biotherapeutics Inc. (SABS)

        The total asset value of SAB Biotherapeutics Inc. (SABS) stood at $ 72 Mln as on 31-Mar-23

        The share price of SAB Biotherapeutics Inc. (SABS) is $0.87 (NASDAQ) as of 06-Dec-2023 15:59 EST. SAB Biotherapeutics Inc. (SABS) has given a return of -18.7% in the last 1 years.

        SAB Biotherapeutics Inc. (SABS) has a market capitalisation of $ 46 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

        The P/B ratio of SAB Biotherapeutics Inc. (SABS) is 1.35 times as on 02-Jun-2023, a -0.47% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of SAB Biotherapeutics Inc. (SABS) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the SAB Biotherapeutics Inc. (SABS) and enter the required number of quantities and click on buy to purchase the shares of SAB Biotherapeutics Inc. (SABS).

        SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

        The CEO & director of Mr. Samuel J. Reich. is SAB Biotherapeutics Inc. (SABS), and CFO & Sr. VP is Dr. Eddie Joe Sullivan Ph.D..

        The promoters of SAB Biotherapeutics Inc. (SABS) have pledged 0% of the total equity as on Mar-23.

        SAB Biotherapeutics Inc. (SABS) Ratios
        Return on equity(%)
        -87.12
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0.02
        Dividend yield(%)
        0

        No, TTM profit after tax of SAB Biotherapeutics Inc. (SABS) was $-29 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $46.19 Mln
        • Revenue (TTM)revenue-information $12.10 Mln
        • Earnings (TTM) earning-information $-29.44 Mln
        • Cash date-information $15.05 Mln
        • Total Debt info $5.93 Mln
        • Insider's Holding 29.55%
        • Liquidity liquidity Moderate
        • 52 Week range week-range $0.37 - 1.45
        • Shares outstanding share-outstanding 50,397,800

        About The Company

        • IPO Date 09-Feb-2021
        • Exec. Chairman Mr. Samuel J. Reich
        • Co-Founder, Pres, CEO & Director Dr. Eddie Joe Sullivan Ph.D.
        • Listing key-listing NASDAQ: SABS
        • Country United States
        • Headquarters headquarters Sioux Falls, SD
        • Website website https://www.sabbiotherapeutics.com
        • Business

          SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds...  that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon